|
CA2608116A1
(en)
|
2005-05-10 |
2006-11-16 |
Intermune, Inc. |
Method of modulating stress-activated protein kinase system
|
|
MY159523A
(en)
*
|
2005-12-21 |
2017-01-13 |
Janssen Pharmaceutica Nv |
Triazolopyridazines as tyrosine kinase modulators
|
|
CA2651979A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Triazolopyridazine derivatives
|
|
ES2474865T3
(es)
*
|
2006-06-22 |
2014-07-09 |
Prana Biotechnology Limited |
Método de tratamiento de un tumor cerebral glioma
|
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
EP2046336A4
(en)
*
|
2006-07-18 |
2010-12-15 |
Cytovia Inc |
3-ARYL-6-ARYL-7H- [1,2,4] TRIAZOLO [3,4-B] [1,3,4] THIADIAZINE AND ANALOGUE AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS AND THEIR USE
|
|
EP2057164A1
(en)
|
2006-08-07 |
2009-05-13 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
CN101796056A
(zh)
*
|
2006-09-18 |
2010-08-04 |
沃泰克斯药物股份有限公司 |
c-MET的杂环抑制剂及其用途
|
|
EP3443958A1
(en)
|
2006-11-22 |
2019-02-20 |
Incyte Holdings Corporation |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
|
UA100684C2
(uk)
*
|
2007-03-15 |
2013-01-25 |
Новартіс Аг |
Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
|
|
EA200971077A1
(ru)
*
|
2007-05-21 |
2010-04-30 |
ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. |
Гетероциклические модуляторы киназы
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
US8188083B2
(en)
|
2007-06-28 |
2012-05-29 |
Abbott Laboratories |
Triazolopyridazines
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
FR2919870B1
(fr)
*
|
2007-08-09 |
2014-05-16 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
|
|
PA8792501A1
(es)
*
|
2007-08-09 |
2009-04-23 |
Sanofi Aventis |
Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
|
|
FR2929613B1
(fr)
*
|
2008-04-02 |
2010-12-31 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
|
|
JP5410431B2
(ja)
|
2007-09-27 |
2014-02-05 |
セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） |
イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
UY31676A1
(es)
|
2008-02-28 |
2009-09-30 |
|
"derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
NZ589622A
(en)
|
2008-05-21 |
2012-10-26 |
Incyte Corp |
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
|
CA3034994A1
(en)
|
2008-06-03 |
2009-12-10 |
Intermune, Inc. |
Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
|
|
DE102008028905A1
(de)
*
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
ES2393693T3
(es)
|
2008-11-19 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Un derivado de triazolotiadiazol como inhibidor de la proteína-quinasa c-Met
|
|
JP2012509342A
(ja)
|
2008-11-20 |
2012-04-19 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
MY160526A
(en)
|
2008-12-22 |
2017-03-15 |
Merck Patent Gmbh |
Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
|
|
DE102008062825A1
(de)
*
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
FR2941949B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941952B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941950B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941951B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
WO2010092371A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
|
JP2012519731A
(ja)
*
|
2009-03-09 |
2012-08-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ニコチン受容体およびｇａｂａａ受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
|
|
SI2414369T1
(sl)
|
2009-04-02 |
2015-12-31 |
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii |
Derivati imidazo(2,1-b)(1,3,4)tiadiazola
|
|
JP2012528185A
(ja)
*
|
2009-05-28 |
2012-11-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔタンパク質キナーゼの置換ピラゾール阻害剤
|
|
KR20120030110A
(ko)
*
|
2009-05-28 |
2012-03-27 |
버텍스 파마슈티칼스 인코포레이티드 |
ｃ-ＭＥＴ 단백질 키나제의 아미노피라졸 트리아졸로티아디아졸 억제제
|
|
WO2010138673A1
(en)
*
|
2009-05-28 |
2010-12-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of c-met protein kinase
|
|
UA108618C2
(uk)
*
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
KR20120089643A
(ko)
|
2009-08-12 |
2012-08-13 |
노파르티스 아게 |
헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
|
|
IN2012DN01453A
(cg-RX-API-DMAC10.html)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
|
EA025466B1
(ru)
|
2009-12-31 |
2016-12-30 |
Хатчисон Медифарма Лимитед |
Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
|
|
ES2608329T3
(es)
|
2010-02-03 |
2017-04-07 |
Incyte Holdings Corporation |
Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
EP2569315A1
(en)
|
2010-05-14 |
2013-03-20 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
NZ604306A
(en)
|
2010-05-17 |
2015-02-27 |
Incozen Therapeutics Pvt Ltd |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
|
EP2576568A1
(en)
|
2010-05-27 |
2013-04-10 |
Vertex Pharmaceuticals Incorporated |
An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
|
|
US20130315895A1
(en)
|
2010-07-01 |
2013-11-28 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
|
AR085183A1
(es)
*
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
EP2710003A1
(en)
|
2011-05-16 |
2014-03-26 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
MD20140044A2
(ro)
|
2011-11-11 |
2014-08-31 |
Pfizer Inc. |
2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
|
|
WO2013134562A1
(en)
|
2012-03-09 |
2013-09-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
TW201341367A
(zh)
|
2012-03-16 |
2013-10-16 |
Axikin Pharmaceuticals Inc |
３，５－二胺基吡唑激酶抑制劑
|
|
US9815831B2
(en)
|
2012-03-30 |
2017-11-14 |
Rhizen Pharmaceuticals Sa |
3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
|
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
|
DK2935228T3
(en)
|
2012-12-20 |
2017-10-30 |
Inception 2 Inc |
TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF
|
|
SG11201601066VA
(en)
|
2013-09-06 |
2016-03-30 |
Inception 2 Inc |
Triazolone compounds and uses thereof
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
EP3053923B1
(en)
|
2013-09-30 |
2018-04-11 |
Korea Research Institute of Chemical Technology |
Triazolopyrazine derivatives as tyrosin kinase inhibitors
|
|
GB201321745D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
CA2943363A1
(en)
|
2014-04-02 |
2015-10-08 |
Intermune, Inc. |
Anti-fibrotic pyridinones
|
|
US10398774B2
(en)
|
2014-12-09 |
2019-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against AXL
|
|
SG11201705088VA
(en)
|
2014-12-23 |
2017-07-28 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
EP3285764B1
(en)
*
|
2015-03-31 |
2024-03-27 |
University of Vermont and State Agricultural College |
Triazolopyridazines for treating cryptosporidiosis
|
|
SG11201708407TA
(en)
|
2015-05-05 |
2017-11-29 |
Pfizer |
2-thiopyrimidinones
|
|
WO2016208744A1
(ja)
|
2015-06-25 |
2016-12-29 |
大鵬薬品工業株式会社 |
線維症治療剤
|
|
US10421756B2
(en)
|
2015-07-06 |
2019-09-24 |
Rodin Therapeutics, Inc. |
Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
|
|
HRP20211864T1
(hr)
|
2015-07-06 |
2022-03-04 |
Alkermes, Inc. |
Inhibitori hetero-halo histonske deacetilaze
|
|
UY36949A
(es)
|
2015-10-14 |
2017-04-28 |
Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware |
2,4-dihidroxi-nicotinamidas como agonistas de apj
|
|
EP3383860B1
(en)
|
2015-12-04 |
2021-01-20 |
Bristol-Myers Squibb Company |
Apelin receptor agonists and methods of use
|
|
CA3008630A1
(en)
|
2015-12-16 |
2017-06-22 |
Bristol-Myers Squibb Company |
Heteroarylhydroxypyrimidinones as agonists of the apj receptor
|
|
AU2017238504B2
(en)
|
2016-03-24 |
2021-05-27 |
Bristol-Myers Squibb Company |
6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
|
|
GR1009565B
(el)
*
|
2016-07-14 |
2019-08-06 |
Galenica Α.Ε. |
Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
|
|
HRP20220223T1
(hr)
|
2017-01-11 |
2022-04-29 |
Alkermes, Inc. |
Biciklički inhibitori histon deacetilaze
|
|
CA3053739C
(en)
|
2017-02-15 |
2023-02-14 |
Taiho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
|
KR102420892B1
(ko)
*
|
2017-05-26 |
2022-07-14 |
쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 |
요산 배출을 촉진시키는 urat1 억제제
|
|
EP3652165B1
(en)
*
|
2017-07-12 |
2021-08-25 |
Bristol-Myers Squibb Company |
Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
|
|
PL3664802T3
(pl)
|
2017-08-07 |
2022-07-11 |
Alkermes, Inc. |
Bicykliczne inhibitory deacetylaz histonowych
|
|
JP7074760B2
(ja)
|
2017-09-08 |
2022-05-24 |
大鵬薬品工業株式会社 |
抗腫瘍剤及び抗腫瘍効果増強剤
|
|
JP7590183B2
(ja)
|
2018-03-13 |
2024-11-26 |
武田薬品工業株式会社 |
血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
|
|
EP4477220A3
(en)
|
2019-09-18 |
2025-02-26 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof
|
|
EP4031245A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
TR202009388A1
(tr)
*
|
2020-06-17 |
2021-12-21 |
Anadolu Ueniversitesi |
Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
|
|
TR202010296A1
(tr)
|
2020-06-30 |
2022-01-21 |
Anadolu Ueniversitesi |
Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
|
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
CN117355523A
(zh)
*
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
血浆激肽释放酶的多环抑制剂
|